Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28922144 | 0.97 | KDM4E (0.51) | KDM4ECA1CA2CA7CA9 | |
| Methyl Alcohol SCHEMBL27577395 | 0.95 | KDM4E (0.54) | KDM4ECA1CA2CA7CA9 | |
| Chloromethane SCHEMBL27930402 | 0.95 | KDM4E (0.50) | KDM4ECA1CA2CA7CA9 | |
| Formaldehyde SCHEMBL27577576 | 0.93 | KDM4E (0.53) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL13232420 | 0.89 | KDM4E (0.46) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL8344052 | 0.89 | KDM4E (0.46) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL27774616 | 0.87 | KDM4E (0.53) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL7443902 | 0.86 | KDM4E (0.47) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL282241 | 0.86 | KDM4E (0.47) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL7816151 | 0.86 | KDM4E (0.47) | KDM4ECA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029153-A | Aromatic hydrocarbon receptor modulator compound, and preparation method and application thereof | 德明药泰生物技术（深圳）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250282730-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2025-09-11 | — | — | US | disclosed |
| WO-2025082312-A1 | AROMATIC HYDROCARBON RECEPTOR MODULATOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 德明药泰生物技术（深圳）有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-12252471-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2025-03-18 | — | — | US | disclosed |
| WO-2024152993-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 上海泽德曼医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| CN-118317952-A | Heterocyclic substituted phenol derivatives, process for their preparation and their use | 上海泽德曼医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20070179154-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| WO-2005042530-A1 | RSV POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2005-05-12 | — | — | WO | disclosed |
| EP-0295882-B1 | PROCESS FOR INTERMEDIATES TO LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0295882-A1 | Process for intermediates to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4777299-A | Process for leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1988-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252471-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | KDM4E 2743/4885CA1 3913/4885CA2 2298/4885 |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | KDM4E 4465/4885CA1 4501/4885CA2 2690/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 3520/4885CA1 3414/4885CA2 4099/4885 |
| US-20250282730-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | KDM4E 2743/4885CA1 3913/4885CA2 2298/4885 |
| US-20070179154-A1 | Coumarin derivatives, process for their production and use thereof | CBR1, CBR3, ACAT2 | KDM4E 1132/4885CA1 578/4885CA2 789/4885 |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | KDM4E 2743/4885CA1 3913/4885CA2 2298/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | KDM4E 201/4885CA1 4880/4885CA2 4794/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KDM4E 1393/4885CA1 3875/4885CA2 1264/4885 |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | NPSR1, VIP, OPRK1 | KDM4E 1960/4885CA1 3189/4885CA2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.